Financial insights of CAI

MyFinsight

For the quarter ending 2026-03-31, CAI made $216,174K in revenue. -$510K in net income. Net profit margin of -0.24%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	216,174	214,687*	216,833	181,398
Cost of services-Molecular Profiling Services	72,884	67,305*	66,980	65,321
Cost of services-Pharma Research And Development Services	1,942	-	-	2,392
Selling and marketing expense	45,043	42,216*	41,267	42,260
General and administrative expense (see note 8)	59,708	50,455*	51,973	64,367
Research and development expense	31,315	31,578*	21,624	25,047
Total costs and operating expenses	210,892	191,553*	184,191	199,387
Income (loss) from operations	5,282	23,134*	32,642	-17,989
Interest income	6,834	3,030*	7,360	1,618
Interest expense	12,809	7,781*	13,507	19,208
Changes in fair value of financial instruments	0	-22,358*	-2,081	-17,870
Other income (expense), net	49	7,085*	-89	-18,341
Total other expense, net	-5,926	-20,024*	-8,317	-53,801
Gain before income taxes and income tax benefit	-644	3,110*	24,325	-71,790
Income tax benefit	-134	0*	0	0
Net gain	-510	3,110*	24,325	-71,790
Deemed dividend from series d redeemable convertible preferred stock (see note 6)	-	-192,218*	0	384,436
Adjustments of redeemable convertible preferred stock to redemption value	0	-6,023*	0	60,971
Net gain attributable to common shareholders basic	-510	201,351	24,325	-517,197
Net gain attributable to common shareholders diluted	-510	201,351	24,325	-517,197

Basic EPS	0	1.204	0.09	-7.97
Diluted EPS	0	1.204	0.08	-7.97
Basic Average Shares	282,562,013	167,205,616*	282,099,073	64,918,988
Diluted Average Shares	282,562,013	167,205,616*	297,211,838	64,918,988

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.